- United States
- /
- Life Sciences
- /
- NYSE:IQV
IQVIA (IQV): Reassessing Valuation After Earnings and EPS Beat Against Consensus Estimates
Reviewed by Simply Wall St
IQVIA Holdings (IQV) just posted quarterly results that cleared the bar on both revenue and earnings, with organic growth and helpful currency shifts pushing sales up 5.2% and adjusted EPS up 6% year over year.
See our latest analysis for IQVIA Holdings.
Those solid quarterly beats come on top of a strong run, with IQVIA’s share price up a robust 23.45% over the past three months and its 11.85% one year total shareholder return pointing to gradually improving sentiment rather than euphoric momentum.
If this earnings surprise has you thinking about what else is working in life sciences, it could be a good moment to explore healthcare stocks for more ideas.
With revenue and earnings still climbing, the stock trading about 10% below analyst targets, and intrinsic value models hinting at a larger discount, is IQVIA a genuine value opportunity or is the market already pricing in years of growth?
Most Popular Narrative Narrative: 8.2% Undervalued
With IQVIA last closing at $227.24 versus a narrative fair value of $247.50, the story leans toward upside if the long range forecasts land.
Continued investment in and deployment of proprietary platforms and agentic AI solutions, coupled with strategic collaborations and industry recognitions, increase switching costs and provide competitive barriers, positioning IQVIA to capture greater market share and support long-term revenue growth and margin improvement.
Curious how steady, mid single digit growth expectations can still justify a richer future earnings multiple and rising margins? The narrative leans on a powerful mix of backlog strength, disciplined share count reduction, and a profitability upgrade that reshapes IQVIA's long term earnings base. Want to see exactly how those moving parts stack up into that fair value?
Result: Fair Value of $247.50 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, a tougher CRO pricing environment and high leverage could pressure margins and limit flexibility, which could quickly undermine the upbeat earnings and valuation narrative.
Find out about the key risks to this IQVIA Holdings narrative.
Build Your Own IQVIA Holdings Narrative
If you would rather dig into the numbers yourself and shape a different storyline, you can build a custom view in just a few minutes, Do it your way.
A great starting point for your IQVIA Holdings research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
Ready for more smart stock ideas?
Before markets move on without you, tap into fresh opportunities across sectors using the Simply Wall St Screener and line up your next potential winners today.
- Secure potential growth and downside protection by targeting companies with steady cash flows and compelling valuations through these 915 undervalued stocks based on cash flows that might not stay cheap for long.
- Capitalize on breakthrough automation and data intelligence trends by zeroing in on innovators driving healthcare transformation with these 30 healthcare AI stocks before the crowd catches on.
- Boost your portfolio income by focusing on reliable payers that show both yield and resilience using these 14 dividend stocks with yields > 3% to spot candidates for long term compounding.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About NYSE:IQV
IQVIA Holdings
Provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific.
Good value with limited growth.
Similar Companies
Market Insights
Weekly Picks

Crazy Undervalued 42 Baggers Silver Play (Active & Running Mine)

Fiducian: Compliance Clouds or Value Opportunity?
Willamette Valley Vineyards (WVVI): Not-So-Great Value
Recently Updated Narratives
TXT will see revenue grow 26% with a profit margin boost of almost 40%
Significantly undervalued gold explorer in Timmins, finally getting traction
Moderation and Stabilisation: HOLD: Fair Price based on a 4-year Cycle is $12.08
Popular Narratives

MicroVision will explode future revenue by 380.37% with a vision towards success

NVDA: Expanding AI Demand Will Drive Major Data Center Investments Through 2026
